RD-Biotech establishes itself in monoclonal antibodies market

27 March 2017


The SME of Besançon bought Diaclone in 2012, then participated in the creation of SynAbs Belgian start-up in 2015. Business is booming.


Philippe Dulieu, PhD in biochemistry,  is forming a small group that counts in the world of the monoclonal antibodies. These molecules - descended from a single strain of lymphocytes, the same as the immune system produced naturally - were originally intended for diagnostic methods, but are increasingly used as therapeutic solutions.


Working on synergies


In 2002, Philippe Dulieu founded RD-Biotech. This service company offers services and products dedicated for the  pharmaceutical and the biotechnology industries in France, Switzerland, Europe and the United States. RD Biotech targets very large industrial companies such as Sanofi, but also small players who have not yet facilities, but have already raised funds, and for which the Besançon team is building prototypes. "Our know-how is to develop molecules in the preclinical stage, then medicines" he explains. Ten years later, in 2012, RD-Biotech bought Diaclone, a spin-off from EFS Bourgogne-Franche-Comté, which was taken over a few years earlier by an American group, Gen Probe, who had not the key elements to increase the value of the latter. The holding Biotech Investissement was born that year to support both structures.


This return to French capital and a clear strategy have restored Diaclone to its full potential. Founded in 1986, Diaclone produces diagnostic tests and antibodies that have become references in the market. "The respective know-how of RD-Biotech and Diaclone are complementary, the two companies are customers and suppliers of each other," adds Philippe Dulieu, President of Biotech Investissement. The third element of the rocket was added at the end of 2015 with the Biotech Investissement stakes in Synabs, a Belgian start-up that exploits a license for other antibodies developed by the University of Louvain. "We thus have a one-stop-shop solution, a symbiosis of markets and a synergy in terms of technologies. "


Based in Besançon, the group employs 55 people. It reached € 6 million in sales in 2016, marked by RD-Biotech's 50% growth in the last two years .

With the rise of biotherapeutics, RD-Biotech has a bright future ahead. Next step : own premises.



More information on




SynAbs inks agreement with Dianova GmbH as new distributor for its unique catalogue of monoclonal antibodies in Germany

 13 Jan 2017


SynAbs is proud to announce strategic deal with successful company Dianova. Dianova has already demonstrated a huge knowledge and expertise in monoclonal antibodies and will consequently extend its catalogue with unique mAbs references from SynAbs. Under the terms of the agreement, Dianova will have access to unique portfolio of rats and guinea pigs mAbs to address German territory needs in R&D and IVD fields.


Kristine Fischer - Director Business Development dianova GmbH

Warburgstrasse 45

20354 Hamburg


Phone: +49 40 45 06 78 10 - Fax: +49 40 45 06 74 90



SynAbs appoints LuBioScience GmbH as new distributor for its unique catalogue of monoclonal antibodies in Switzerland

SynAbs is proud to appoint LuBioSience as its new distributor for Switzerland. LuBioScience has a seasoned team and expertise in selling biochemicals, including the specific monoclonal antibodies of SynAbs, in particular the anti-species which should be welcomed by the Swiss Biopharma R&D and IVD sector.


Roland Schärli - CEO LuBioScience GmbH

Töpferstrasse 5

PO Box

6004 Lucerne


Phone: +41 41 417 02 80 - Fax: +41 41 417 02 89



Guinea pig monoclonal antibodies : a new promising tool for R&D, IVD and therapeutics

Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some companies have developed fusion cell lines to

generate monoclonal antibodies in rabbit (Abcam-Epitomics) or in sheep (Bioventix). However, these two tools are not totally satisfactory whether in terms of cost, stability or productivity.

SynAbs has therefore opted to develop its own myeloma cell line to manufacture guinea pig monoclonal antibodies and offer more efficient investigation tools for researchers.

Read More

Our Antibody products

SynAbs proposes a catalog of more than 1,000 rat and mice monoclonal antibodies!

>> to see our catalog


Custom Antibody Services

SynAbs maximizes the success rate and the quality of the mAbs generated in rats and mice. >> more about our technology


The Rat mAbs  experts

SynAbs is a dedicated Monoclonal Antibody Manufacturing Center.

>> read more about our expertise

The benefits of our technology?

  1. Higher specificity
  2. Higher affinity
  3. Excellent results, even for small and difficult antigens
  4. Additional epitope recognition
  5. Access to the lymph nodes
  6. Rat Fc close to the human one
  7. Ideal for mice antigens

Our agenda

When ?

Feb 2nd - Feb 3rd

Feb 16th

April 3rd - April 5th

May 9th - May 10th

May 16th - May 18th

May 18th

May 23rd - May 25th

June 21st

July 30th - August 3rd

October 17th

Nov 11th - Nov 16th















Where ?

Evry, France, Buzz4Bio Bioproduction

Rotterdam, The Netherlands, Innovation for Health

Singapour, Singapour, Medlab

Eindhoven, The Netherlands, Biomedica

Hannover, Germany, Biotechnica

Ghent, Belgium, Knowledge 4 Growth

Tel Aviv, Israël, BioMed

Oxford, United Kingdom, Pivotal Scientific

San Diego, USA, AACC

Yokohama, Japan, BioJapan

Dusseldorf, Germany, Medica